TABLE 1.
Demographic and summary statistics.
|
Overall (N = 424) |
Sample with known A status (Aim 2: N = 382) |
Amyloid neg CU subset (Aim 1: N = 226) |
|
|---|---|---|---|
| Age at first plasma, mean (SD) | 61.79 (6.89) | 62.01 (6.77) | 60.94 (6.95) |
| Age at last plasma, mean (SD) | 66.59 (6.86) | 66.84 (6.71) | 64.50 (6.95) |
| Years between visits, mean (SD) | 2.48 (0.54) | 2.48 (0.54) | 2.50 (0.55) |
| Number of plasma samples, median [IQR] | 3 [3, 3] | 3 [3, 3] | 3 [3, 3] |
| Age at last amyloid PET, mean (SD) | 65.90 (6.91) | 65.82 (6.90) | 65.87 (6.87) |
| Female, n (%) | 286 (67.45) | 256 (67.02) | 156 (69.0) |
| Non‐Hispanic White, n (%) | 402 (94.8) | 364 (95.3) | 214 (94.7) |
| APOE ε4 carrier, n (%) * | 163 (39.5) | 143 (38.1) | 68 (30.6) |
| APOE risk score, mean (SD) * | 0.63 (1.07) | 0.60 (1.05) | 0.43 (0.97) |
| Education, mean (SD) | 16.13 (2.66) | 16.13 (2.65) | 16.03 (2.69) |
| Baseline cognitive status, n (%) | |||
| CU‐S | 337 (79.3) | 301 (78.8) | 186 (82.3) |
| CU‐D | 75 (17.6) | 69 (18.1) | 40 (17.7) |
| MCI | 9 (2.1) | 9 (2.4) | |
| Other | 3 (0.7) | 3 (0.8) | |
| Last cognitive status, n (%) | |||
| CU‐S | 367 (86.6) | 331 (86.6) | 206 (91.2) |
| CU‐D | 42 (9.9) | 38 (9.9) | 20 (8.8) |
| MCI | 14 (3.3) | 12 (3.1) | |
| Dementia | 1 (0.2) | 1 (0.3) | |
| Baseline p‐tau217, pg/mL, median [IQR] | 0.33 [0.24, 0.45] | 0.33 [0.24, 0.45] | 0.30 [0.23, 0.40] |
| Last p‐tau217, pg/mL, median [IQR] | 0.37 [0.28, 0.59] | 0.37 [0.28, 0.59] | 0.34 [0.26, 0.44] |
| Baseline Aβ42/40, median [IQR] | 0.07 [0.06, 0.08] | 0.07 [0.06, 0.08] | 0.07 [0.06, 0.08] |
| Last Aβ42/40, median [IQR] | 0.07 [0.06, 0.08] | 0.07 [0.06, 0.08] | 0.07 [0.06, 0.08] |
| Baseline p‐tau181, pg/mL, median [IQR] | 2.31 [1.81, 3.06] | 2.32 [1.81, 3.04] | 2.22 [1.75, 2.92] |
| Last p‐tau181, pg/mL, median [IQR] | 2.41 [1.83, 3.12] | 2.41 [1.84, 3.11] | 2.21 [1.74, 2.85] |
| Baseline p‐tau231, pg/mL, median [IQR] | 10.92 [8.15, 13.90] | 10.94 [8.31, 13.80] | 10.60 [8.08, 13.15] |
| Last p‐tau231, pg/mL, median [IQR] | 11.50 [8.71, 14.30] | 11.50 [8.78, 14.30] | 10.89 [8.52, 13.40] |
| Baseline GFAP, pg/mL, median [IQR] | 102.00 [75.33, 139.00] | 102.00 [76.60, 140.75] | 97.60 [75.17, 130.75] |
| Last GFAP, pg/mL, median [IQR] | 103.50 [74.88, 144.25] | 105.00 [75.30, 146.75] | 101.00 [72.25, 137.75] |
| Baseline NfL, pg/mL, median [IQR] | 15.65 [11.60, 21.72] | 15.85 [12.10, 21.78] | 15.00 [11.53, 20.48] |
| Last NfL, pg/mL, median [IQR] | 19.25 [14.30, 26.02] | 19.30 [14.62, 26.08] | 18.40 [14.05, 25.53] |
| Amyloid CL, median [IQR] | 3.75 [−0.70, 12.65] | 3.75 [−0.70, 12.65] | 2.27 [−2.18, 5.24] |
| Overall A+, n (%) | 71 (18.6) | 71 (18.6) | 0 |
*
n = 4 is missing in healthy control data set, n = 7 is missing in sample with known A status, n = 12 is missing in overall data set.
Abbreviation: CL, Centiloid; CU‐S, cognitively unimpaired‐stable; CU‐D, CU‐declining; MCI, mild cognitive impairment; Other, other cognitive impairment.